Concepts (195)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thrombocytopenia | 9 | 2022 | 113 | 2.980 |
Why?
|
| Cardiovascular Diseases | 5 | 2025 | 367 | 2.290 |
Why?
|
| Platelet Count | 5 | 2018 | 111 | 2.260 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 8 | 2022 | 216 | 1.310 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 5 | 2018 | 67 | 1.050 |
Why?
|
| Registries | 7 | 2015 | 386 | 0.940 |
Why?
|
| Vitamin D Deficiency | 1 | 2025 | 31 | 0.920 |
Why?
|
| Pregnancy | 7 | 2022 | 1191 | 0.860 |
Why?
|
| Dyslipidemias | 1 | 2024 | 32 | 0.850 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2024 | 48 | 0.840 |
Why?
|
| Vaccines | 1 | 2022 | 33 | 0.740 |
Why?
|
| Atherosclerosis | 1 | 2022 | 96 | 0.710 |
Why?
|
| Adolescent | 10 | 2025 | 3126 | 0.650 |
Why?
|
| Hemolytic-Uremic Syndrome | 3 | 2015 | 81 | 0.650 |
Why?
|
| ADAM Proteins | 4 | 2014 | 103 | 0.640 |
Why?
|
| Pregnancy Complications, Hematologic | 4 | 2021 | 38 | 0.610 |
Why?
|
| Humans | 34 | 2025 | 28155 | 0.600 |
Why?
|
| Thrombotic Microangiopathies | 2 | 2018 | 24 | 0.600 |
Why?
|
| Placenta | 1 | 2018 | 78 | 0.580 |
Why?
|
| Public Health Surveillance | 1 | 2017 | 6 | 0.560 |
Why?
|
| Young Adult | 9 | 2025 | 2737 | 0.560 |
Why?
|
| Risk Factors | 7 | 2025 | 2087 | 0.550 |
Why?
|
| Pregnancy Complications | 1 | 2018 | 111 | 0.540 |
Why?
|
| Incidence | 3 | 2025 | 562 | 0.470 |
Why?
|
| Female | 21 | 2025 | 15183 | 0.470 |
Why?
|
| Quinine | 1 | 2015 | 24 | 0.470 |
Why?
|
| Proportional Hazards Models | 3 | 2025 | 226 | 0.460 |
Why?
|
| Adult | 13 | 2025 | 7764 | 0.460 |
Why?
|
| United States | 7 | 2025 | 2150 | 0.360 |
Why?
|
| Stroke | 3 | 2025 | 252 | 0.350 |
Why?
|
| Indians, North American | 2 | 2025 | 517 | 0.340 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 3 | 2016 | 94 | 0.310 |
Why?
|
| Prevalence | 3 | 2025 | 494 | 0.280 |
Why?
|
| Male | 15 | 2025 | 13505 | 0.280 |
Why?
|
| Aged | 6 | 2025 | 5416 | 0.270 |
Why?
|
| Blood Pressure | 2 | 2025 | 355 | 0.270 |
Why?
|
| Vitamin D | 1 | 2025 | 50 | 0.230 |
Why?
|
| Depressive Disorder, Major | 2 | 2016 | 127 | 0.230 |
Why?
|
| Artificial Intelligence | 1 | 2025 | 54 | 0.220 |
Why?
|
| Lipoproteins, LDL | 1 | 2024 | 36 | 0.220 |
Why?
|
| Child | 6 | 2022 | 2249 | 0.220 |
Why?
|
| Prospective Studies | 3 | 2024 | 1253 | 0.210 |
Why?
|
| Mass Screening | 1 | 2025 | 152 | 0.210 |
Why?
|
| Blood Platelets | 2 | 2018 | 206 | 0.200 |
Why?
|
| Child, Preschool | 3 | 2021 | 1145 | 0.200 |
Why?
|
| Cholesterol | 1 | 2024 | 200 | 0.200 |
Why?
|
| Antibodies | 2 | 2015 | 124 | 0.190 |
Why?
|
| Recurrence | 4 | 2022 | 323 | 0.190 |
Why?
|
| Snacks | 1 | 2021 | 5 | 0.190 |
Why?
|
| Myocardial Ischemia | 1 | 2022 | 73 | 0.190 |
Why?
|
| Lunch | 1 | 2021 | 10 | 0.190 |
Why?
|
| Food Preferences | 1 | 2021 | 20 | 0.190 |
Why?
|
| Vegetables | 1 | 2021 | 28 | 0.190 |
Why?
|
| Oklahoma | 5 | 2021 | 1005 | 0.190 |
Why?
|
| Anemia, Hemolytic | 1 | 2021 | 22 | 0.180 |
Why?
|
| Attitude to Health | 1 | 2021 | 89 | 0.180 |
Why?
|
| ADAMTS13 Protein | 4 | 2014 | 126 | 0.180 |
Why?
|
| Feeding Behavior | 1 | 2021 | 102 | 0.170 |
Why?
|
| Myocardial Infarction | 1 | 2022 | 346 | 0.160 |
Why?
|
| Songbirds | 1 | 2019 | 4 | 0.160 |
Why?
|
| Animal Migration | 1 | 2019 | 8 | 0.160 |
Why?
|
| Genetics, Population | 1 | 2019 | 73 | 0.150 |
Why?
|
| Chorionic Villi | 1 | 2018 | 7 | 0.150 |
Why?
|
| Blood Cell Count | 1 | 2018 | 15 | 0.150 |
Why?
|
| Blood Specimen Collection | 1 | 2018 | 14 | 0.150 |
Why?
|
| Capillaries | 1 | 2018 | 33 | 0.150 |
Why?
|
| Fetal Blood | 1 | 2018 | 39 | 0.150 |
Why?
|
| Mothers | 2 | 2016 | 122 | 0.150 |
Why?
|
| Atrial Fibrillation | 1 | 2022 | 403 | 0.140 |
Why?
|
| Reference Values | 1 | 2018 | 200 | 0.140 |
Why?
|
| Infant, Newborn | 3 | 2022 | 889 | 0.140 |
Why?
|
| Hemoglobins | 1 | 2018 | 118 | 0.140 |
Why?
|
| Blood Coagulation | 1 | 2018 | 118 | 0.140 |
Why?
|
| Postpartum Period | 1 | 2017 | 72 | 0.140 |
Why?
|
| Gestational Age | 1 | 2017 | 146 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2014 | 42 | 0.130 |
Why?
|
| Rituximab | 2 | 2014 | 63 | 0.130 |
Why?
|
| Adaptation, Physiological | 1 | 2017 | 169 | 0.130 |
Why?
|
| Psychological Tests | 1 | 2016 | 21 | 0.130 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2016 | 28 | 0.130 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 98 | 0.130 |
Why?
|
| Middle Aged | 7 | 2025 | 7164 | 0.130 |
Why?
|
| Autoantibodies | 1 | 2018 | 474 | 0.120 |
Why?
|
| Infant | 2 | 2022 | 1010 | 0.120 |
Why?
|
| Pentostatin | 1 | 2015 | 4 | 0.120 |
Why?
|
| Wisconsin | 1 | 2015 | 8 | 0.120 |
Why?
|
| Organoplatinum Compounds | 1 | 2015 | 24 | 0.120 |
Why?
|
| Ambulatory Care Facilities | 1 | 2015 | 54 | 0.110 |
Why?
|
| Back Pain | 1 | 2014 | 20 | 0.110 |
Why?
|
| Vancomycin | 1 | 2015 | 58 | 0.110 |
Why?
|
| Dopamine | 1 | 2014 | 21 | 0.110 |
Why?
|
| Deoxycytidine | 1 | 2015 | 66 | 0.110 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2014 | 13 | 0.110 |
Why?
|
| Databases, Factual | 2 | 2013 | 255 | 0.110 |
Why?
|
| Diagnostic Errors | 1 | 2014 | 32 | 0.110 |
Why?
|
| Hypotension | 1 | 2014 | 19 | 0.110 |
Why?
|
| Necrosis | 1 | 2014 | 84 | 0.110 |
Why?
|
| Depression | 1 | 2016 | 215 | 0.110 |
Why?
|
| Albuminuria | 1 | 2014 | 23 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 523 | 0.110 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 41 | 0.110 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2014 | 7 | 0.110 |
Why?
|
| Pre-Eclampsia | 1 | 2014 | 49 | 0.110 |
Why?
|
| Age Distribution | 1 | 2013 | 73 | 0.110 |
Why?
|
| Recovery of Function | 1 | 2014 | 118 | 0.110 |
Why?
|
| Japan | 1 | 2013 | 24 | 0.110 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 20 | 0.100 |
Why?
|
| Immunologic Factors | 1 | 2013 | 49 | 0.100 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2014 | 173 | 0.100 |
Why?
|
| Sex Factors | 1 | 2013 | 465 | 0.090 |
Why?
|
| Age Factors | 1 | 2013 | 733 | 0.090 |
Why?
|
| Fatigue | 1 | 2011 | 64 | 0.090 |
Why?
|
| Methods | 1 | 2010 | 27 | 0.090 |
Why?
|
| Cause of Death | 2 | 2025 | 73 | 0.090 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2010 | 13 | 0.090 |
Why?
|
| Data Mining | 1 | 2010 | 15 | 0.080 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 45 | 0.080 |
Why?
|
| Pharmaceutical Preparations | 1 | 2010 | 46 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2014 | 613 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2025 | 521 | 0.080 |
Why?
|
| Morbidity | 2 | 2022 | 59 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2016 | 889 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 1015 | 0.070 |
Why?
|
| Retrospective Studies | 1 | 2013 | 2557 | 0.060 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2013 | 991 | 0.060 |
Why?
|
| Blood Pressure Determination | 1 | 2025 | 27 | 0.060 |
Why?
|
| Telomere | 1 | 2025 | 35 | 0.060 |
Why?
|
| Cluster Analysis | 1 | 2025 | 124 | 0.060 |
Why?
|
| American Heart Association | 1 | 2024 | 21 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2025 | 128 | 0.060 |
Why?
|
| Machine Learning | 1 | 2025 | 85 | 0.050 |
Why?
|
| Goals | 1 | 2024 | 34 | 0.050 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 969 | 0.050 |
Why?
|
| Vitamin K | 1 | 2022 | 39 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2022 | 2383 | 0.050 |
Why?
|
| Fibrinolytic Agents | 1 | 2022 | 70 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2022 | 190 | 0.050 |
Why?
|
| Plasma | 1 | 2022 | 32 | 0.050 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2021 | 21 | 0.050 |
Why?
|
| Child Day Care Centers | 1 | 2021 | 25 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2022 | 191 | 0.040 |
Why?
|
| Disease Management | 1 | 2021 | 88 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 265 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2022 | 294 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 242 | 0.040 |
Why?
|
| Louisiana | 1 | 2019 | 7 | 0.040 |
Why?
|
| North Carolina | 1 | 2019 | 16 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2019 | 51 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2018 | 6 | 0.040 |
Why?
|
| Trimethoprim | 1 | 2018 | 6 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2019 | 125 | 0.040 |
Why?
|
| Flavonoids | 1 | 2018 | 33 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2018 | 16 | 0.040 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2018 | 19 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2018 | 63 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 2018 | 20 | 0.040 |
Why?
|
| Influenza Vaccines | 1 | 2018 | 51 | 0.040 |
Why?
|
| Proteasome Inhibitors | 1 | 2018 | 26 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2019 | 243 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 113 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 555 | 0.030 |
Why?
|
| Peripartum Period | 1 | 2016 | 5 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 773 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2016 | 100 | 0.030 |
Why?
|
| Depression, Postpartum | 1 | 2016 | 15 | 0.030 |
Why?
|
| Animals | 2 | 2019 | 10415 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2014 | 19 | 0.030 |
Why?
|
| Dobutamine | 1 | 2014 | 7 | 0.030 |
Why?
|
| Catecholamines | 1 | 2014 | 18 | 0.030 |
Why?
|
| Ligation | 1 | 2014 | 40 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2014 | 69 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2014 | 67 | 0.030 |
Why?
|
| Cardiotonic Agents | 1 | 2014 | 28 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2014 | 42 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 75 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2014 | 48 | 0.030 |
Why?
|
| Echocardiography | 1 | 2014 | 108 | 0.030 |
Why?
|
| Bone Marrow | 1 | 2014 | 76 | 0.030 |
Why?
|
| Plasma Exchange | 1 | 2014 | 104 | 0.030 |
Why?
|
| Review Literature as Topic | 1 | 2014 | 10 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2013 | 19 | 0.030 |
Why?
|
| Mortality | 1 | 2013 | 46 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2014 | 141 | 0.030 |
Why?
|
| Internationality | 1 | 2013 | 31 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2013 | 267 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 2014 | 131 | 0.030 |
Why?
|
| Survival Rate | 1 | 2013 | 430 | 0.020 |
Why?
|
| Filgrastim | 1 | 2011 | 7 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 2011 | 15 | 0.020 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2011 | 18 | 0.020 |
Why?
|
| United Kingdom | 1 | 2011 | 75 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 300 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 414 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 969 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 2021 | 0.020 |
Why?
|